SPY457.40+6.90 1.53%
DIA346.61+6.15 1.81%
IXIC15,381.32+127.27 0.83%

BRIEF-Baudax Bio Announces Clinical Program Update For Neuromuscular Blocking Agents

reuters.com · 11/11/2021 07:05
BRIEF-Baudax Bio Announces Clinical Program Update For Neuromuscular Blocking Agents

- Baudax Bio Inc BXRX:

  • BAUDAX BIO ANNOUNCES CLINICAL PROGRAM UPDATE FOR NEUROMUSCULAR BLOCKING AGENTS BX-1000, BX-2000 AND BX-3000

  • BAUDAX BIO INC - BX-2000 AND BX-3000 TO ADVANCE INTO CLINICAL STUDIES IN 2022

  • BAUDAX BIO INC - BX-1000 COMPLETES DOSE-ESCALATION STUDY

  • BAUDAX BIO INC - BX-1000 WAS GENERALLY WELL TOLERATED AND RAPIDLY ACHIEVED MUSCLE PARALYSIS, ALONG WITH COMPLETE SPONTANEOUS RECOVERY

Source text for Eikon: ID:nGNX5GJXNq

Further company coverage: BXRX


((Reuters.Briefs@thomsonreuters.com;;))